JP2024536088A5 - - Google Patents
Info
- Publication number
- JP2024536088A5 JP2024536088A5 JP2024518725A JP2024518725A JP2024536088A5 JP 2024536088 A5 JP2024536088 A5 JP 2024536088A5 JP 2024518725 A JP2024518725 A JP 2024518725A JP 2024518725 A JP2024518725 A JP 2024518725A JP 2024536088 A5 JP2024536088 A5 JP 2024536088A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- oligonucleotide
- target nucleic
- target
- oligonucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248524P | 2021-09-26 | 2021-09-26 | |
| US63/248,524 | 2021-09-26 | ||
| US202263341391P | 2022-05-12 | 2022-05-12 | |
| US63/341,391 | 2022-05-12 | ||
| PCT/US2022/044767 WO2023049477A2 (en) | 2021-09-26 | 2022-09-26 | Compositions for editing mecp2 transcripts and methods thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024536088A JP2024536088A (ja) | 2024-10-04 |
| JP2024536088A5 true JP2024536088A5 (https=) | 2025-10-06 |
Family
ID=85721202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518725A Pending JP2024536088A (ja) | 2021-09-26 | 2022-09-26 | Ｍｅｃｐ２転写物を編集するための組成物及びその方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250135036A1 (https=) |
| EP (1) | EP4404942A2 (https=) |
| JP (1) | JP2024536088A (https=) |
| AU (1) | AU2022349529A1 (https=) |
| CA (1) | CA3232965A1 (https=) |
| WO (1) | WO2023049477A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2872485T3 (pl) | 2012-07-13 | 2021-05-31 | Wave Life Sciences Ltd. | Asymetryczna grupa pomocnicza |
| BR112016016400A2 (pt) | 2014-01-16 | 2017-10-03 | Wave Life Sciences Ltd | Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos |
| IL320434A (en) | 2015-07-22 | 2025-06-01 | Wave Life Sciences Ltd | Oligonucleotide preparations and methods |
| JP2019520339A (ja) | 2016-06-03 | 2019-07-18 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド、その組成物および方法 |
| US11873316B2 (en) | 2016-11-23 | 2024-01-16 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| US11718638B2 (en) | 2017-06-21 | 2023-08-08 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
| CA3072110A1 (en) | 2017-09-18 | 2019-03-21 | Wave Life Sciences Ltd. | Technologies for oligonucleotide preparation |
| SG11202009877XA (en) | 2018-04-12 | 2020-11-27 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods of use thereof |
| US12391942B2 (en) | 2018-05-11 | 2025-08-19 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| JP2022525541A (ja) | 2019-03-20 | 2022-05-17 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド調製に有用な技術 |
| AU2024354150A1 (en) * | 2023-09-28 | 2026-03-12 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| WO2026077951A1 (en) | 2024-10-07 | 2026-04-16 | Vico Therapeutics B.V. | Improved aon for rna editing |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030190626A1 (en) * | 2002-04-09 | 2003-10-09 | Vasulinga Ravikumar | Phosphorothioate monoester modified oligomers |
| US11866697B2 (en) * | 2017-05-18 | 2024-01-09 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| AU2020279751A1 (en) * | 2019-05-21 | 2021-12-02 | Beam Therapeutics Inc. | Methods of editing a single nucleotide polymorphism using programmable base editor systems |
| KR20230118716A (ko) * | 2020-11-08 | 2023-08-11 | 웨이브 라이프 사이언시스 리미티드 | 올리고뉴클레오티드 조성물 및 이의 방법 |
-
2022
- 2022-09-26 EP EP22873722.7A patent/EP4404942A2/en active Pending
- 2022-09-26 AU AU2022349529A patent/AU2022349529A1/en active Pending
- 2022-09-26 CA CA3232965A patent/CA3232965A1/en active Pending
- 2022-09-26 JP JP2024518725A patent/JP2024536088A/ja active Pending
- 2022-09-26 US US18/695,348 patent/US20250135036A1/en active Pending
- 2022-09-26 WO PCT/US2022/044767 patent/WO2023049477A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024536088A5 (https=) | ||
| JP2023548584A5 (https=) | ||
| AU2020257097B2 (en) | Compositions and methods for controlling arthropod parasite and pest infestations | |
| US11673911B2 (en) | Stabilized nucleic acids encoding messenger ribonucleic acid (mRNA) | |
| JP2023535918A (ja) | Ｒｎａ編集用のアンチセンスオリゴヌクレオチド | |
| JP2022519019A (ja) | オリゴヌクレオチド組成物及びその方法 | |
| TW202307207A (zh) | 用於抑制黃嘌呤脫氫酶(XDH)之表現之RNAi藥劑、其醫藥組合物及使用方法 | |
| HK1255699A1 (zh) | Kras表达的调节剂 | |
| TW201210611A (en) | Treatment of Nicotinamide Phosphoribosyltransferase (NAMPT) related diseases by inhibition of natural antisense transcript to NAMPT | |
| CN108410868A (zh) | Gcgr表达的反义调节 | |
| CN105121452A (zh) | 三环核苷和由其制备的寡聚化合物 | |
| JP7463621B2 (ja) | ミトコンドリアアミドキシム還元成分１（ｍａｒｃ１）発現を阻害するための組成物および方法 | |
| US20230235329A1 (en) | Antisense oligonucleotides (aso) for efficient and precise rna editing with endogenous adenosine deaminase acting on rna (adar) | |
| WO2019181946A1 (ja) | 毒性が軽減した核酸 | |
| JP7560616B2 (ja) | 膜貫通型セリンプロテアーゼ６（ｔｍｐｒｓｓ６）発現を阻害するための組成物および方法 | |
| JP2026052054A (ja) | Ｃａｌｍ２のアンチセンスオリゴヌクレオチド | |
| JP7497061B2 (ja) | Ｒｎａ分子、キメラ型ｎａ分子、二本鎖ｒｎａ分子、および二本鎖キメラ型ｎａ分子 | |
| JP5794559B2 (ja) | 間葉系細胞の分化を調節するための薬剤及びその利用 | |
| US20210290653A1 (en) | Modulation of lnc05 expression | |
| AU2006345724B2 (en) | Compositions and methods for the treatment of muscle wasting | |
| WO2022211129A1 (ja) | Ａｔｎ１のアンチセンスオリゴヌクレオチド誘導体 | |
| WO2022211095A1 (ja) | Ｆｇｆｒ３のアンチセンスオリゴヌクレオチド | |
| KR20230104880A (ko) | 올리고뉴클레오티드의 신경교세포로의 선택적 전달 | |
| WO2025026228A1 (zh) | Cfb抑制剂组合物及其应用 | |
| KR102544124B1 (ko) | eIF4E 저해제를 포함하는 eIF4E 활성증가와 관련된 상태의 진단 또는 치료용 조성물 |